Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAPER: Eltrombopag for Sustained Remission in ITP
NCT03524612Phase 2Completed
- Sponsor
- Novartis
- Start
- Nov 2018
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 15
01
Overview
A Phase 2 trial of eltrombopag in immune thrombocytopenia (ITP), sponsored by Novartis. Started Nov 2018; status: completed.
02
Drugs
eltrombopag
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT03524612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03524612.